graph Evidence gap map comparisons
atezolizumab based treatmentnivolumab based treatmentImmune checkpoint association
atezolizumab plus cometinib nivolumab alone nivolumab plus ipilimumab
mML - L1 - BRAF wild 3       
Comparator:  vs pembrolizumab alone;   vs dacarbazine;   vs ipilimumab alone; 
Risk of bias:  low;   some concerns;   high;  NA;